Loading…
Atara Biotherapeutics, Inc. is projected to rise to $12.14 by 2027, a +15% move from its current price of $10.54. ATRA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $9.93 | $10.55 | $11.20 | +0.08% |
| May 30 | $9.69 | $10.56 | $11.50 | +0.15% |
| May 31 | $9.52 | $10.56 | $11.73 | +0.23% |
| Jun 1 | $9.37 | $10.57 | $11.93 | +0.31% |
| Jun 2 | $9.25 | $10.58 | $12.11 | +0.39% |
| Jun 3 | $9.14 | $10.59 | $12.27 | +0.46% |
| Jun 4 | $9.04 | $10.60 | $12.43 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.04 | $10.60 | $12.43 | +0.54% |
| Week 2 | $8.50 | $10.65 | $13.35 | +1.09% |
| Week 3 | $8.13 | $10.71 | $14.12 | +1.63% |
| Week 4 | $7.83 | $10.77 | $14.81 | +2.18% |
| Week 5 | $7.58 | $10.83 | $15.47 | +2.74% |
| Week 6 | $7.37 | $10.89 | $16.09 | +3.29% |
| Week 7 | $7.18 | $10.95 | $16.69 | +3.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Atara Biotherapeutics, Inc. is a healthcare company focused on developing transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of Epstein-Barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.
It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc.
was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Atara Biotherapeutics, Inc. (ATRA) is a healthcare stock with current price $10.54 and market cap $94.97M, ranking 4200.
The stock is trading in a technical frame, with bullish sentiment and RSI14 at 70. The 50-day simple moving average sits at $6.22, while the 200-day simple moving average is $10.14. Nearby support sits at $4.60 and resistance at $10.54, framing a modestly constructive near-term picture.
The 30-day price band runs from $7.08 to $15.68, highlighting appreciable near-term volatility.
Forecasts imply an evolving price outlook over time, with the 2026 average price around $10.54 and a wide min/max band ($4.18 to $14.67) and a 0% ROI, followed by higher averages and favorable ROIs in later years (2027–2050). Long-dated projections show substantial appreciation, including a 2040 average of $73.73 (ROI 599.5%) and a 2050 average of $159.00 (ROI 1408.6%), underscoring the potential for outsized upside alongside significant uncertainty.
A major floor 75.1% below — a decisive break under it would weaken the trend.
The nearest floor, 56.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 37.6% above — clearing it would confirm fresh momentum.
Key ATRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ATRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.75 | Buy | $9.87 | Buy |
| MA 10 | $9.69 | Buy | $9.44 | Buy |
| MA 20 | $8.14 | Buy | $8.48 | Buy |
| MA 50 | $6.22 | Buy | $7.21 | Buy |
| MA 100 | $6.30 | Buy | $7.54 | Buy |
| MA 200 | $10.14 | Buy | $8.70 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.69 | Neutral |
| Stoch RSI (14) | 27.01 | Neutral |
| CCI (20) | 80.69 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.09 | Buy |
| ROC (12) | 26.38 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 2.64 | Buy |
| Awesome (5,34) | 2.90 | Buy |
| Ultimate (7,14,28) | 70.55 | Sell |
| Momentum (10) | 0.73 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 9.95 | Buy |
| ADX (14) | 26.82 | Buy |
| ATR (14) | 0.50 | Info |
The near-term technical picture remains bullish, with sentiment labeled BULLISH and an RSI of 70, indicating strong momentum.
The stock sits above the SMA50 of $6.22 and is near the SMA200 of $10.14, suggesting that the intermediate trend remains constructive. Key support is identified at $4.60, with resistance at $10.54, mapping a near-term range that could cap upside unless momentum accelerates. The 30-day range spans from $7.08 to $15.68, highlighting a relatively wide trading band in the short run.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.18 | $10.54 | $14.67 | 0% | Neutral | |
| $8.73 | $12.14 | $18.25 | +15% | Neutral | |
| $9.02 | $13.30 | $21.26 | +26% | Bullish | |
| $11.45 | $17.77 | $29.78 | +69% | Bullish | |
| $16.10 | $26.19 | $45.65 | +148% | Bullish | |
| $17.34 | $29.47 | $53.15 | +180% | Bullish | |
| $18.51 | $32.81 | $60.99 | +211% | Bullish | |
| $18.60 | $34.33 | $65.56 | +226% | Bullish | |
| $17.94 | $34.43 | $67.40 | +227% | Bullish | |
| $18.10 | $36.10 | $72.31 | +243% | Bullish | |
| $33.18 | $73.73 | $162.18 | +600% | Bullish | |
| $71.55 | $159.00 | $365.71 | +14.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.18 | $10.54 | $12.44 | +0.00% |
| June 2026 | $8.82 | $10.57 | $13.14 | +0.32% |
| July 2026 | $9.27 | $11.31 | $14.41 | +6.94% |
| August 2026 | $9.08 | $11.22 | $14.58 | -0.78% |
| September 2026 | $8.69 | $10.86 | $14.33 | -3.18% |
| October 2026 | $8.99 | $11.35 | $15.19 | +4.51% |
| November 2026 | $9.08 | $11.57 | $15.68 | +1.95% |
| December 2026 | $8.33 | $10.71 | $14.67 | -7.48% |
Click any year to see its month-by-month ATRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ATRA price prediction for 2026 points to an average of $10.54 (low $4.18, high $14.67) — a potential gain of 0% on today's $10.54. A consolidation phase looks the most probable path here.
In 2027, ATRA is projected to trade between $8.73 and $18.25, averaging $12.14 — a potential gain of +15% from today's $10.54. That is up +15% on the projected 2026 average. Price action looks broadly range-bound.
Atara Biotherapeutics, Inc.'s 2028 outlook centres on $13.30, within a $9.02 to $21.26 range. That is up +10% on the projected 2027 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ATRA could reach as high as $29.78, with a base case around $17.77 and support toward $11.45 — roughly +69% from $10.54. Momentum favours further upside here.
Expect ATRA to range from $16.10 to $45.65 through 2030. The $26.19 average target implies a +148% move from current prices. That is up +47% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ATRA price prediction for 2031 points to an average of $29.47 (low $17.34, high $53.15) — a potential gain of +180% on today's $10.54. Momentum favours further upside here.
In 2032, ATRA is projected to trade between $18.51 and $60.99, averaging $32.81 — a potential gain of +211% from today's $10.54. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Atara Biotherapeutics, Inc.'s 2033 outlook centres on $34.33, within a $18.60 to $65.56 range. That is up +5% on the projected 2032 average. That marks a +226% change versus current levels. Momentum favours further upside here.
By 2034, ATRA could reach as high as $67.40, with a base case around $34.43 and support toward $17.94 — roughly +227% from $10.54. Buyers look set to stay in control over this stretch.
Expect ATRA to range from $18.10 to $72.31 through 2035. The $36.10 average target implies a +243% move from current prices. That is up +5% on the projected 2034 average. Momentum favours further upside here.
The ATRA price prediction for 2040 points to an average of $73.73 (low $33.18, high $162.18) — a potential gain of +600% on today's $10.54. Buyers look set to stay in control over this stretch.
In 2050, ATRA is projected to trade between $71.55 and $365.71, averaging $159.00 — a potential gain of +14.1x from today's $10.54. That is up +116% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ATRA today (≈ 94.87666 ATRA) could be worth
$15,085.85
+$14,085.85 (+1409%) by 2050 · US Dollar
Based on the average projected ATRA price of $159 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ATRAwould be worth at today's price.
$1,000 invested in ATRA on May 27, 2025 (≈ 133.511353 ATRA) would be worth
$1,407.21
+$407.21 (+40.7%) today · 1.41× · US Dollar
Based on a ATRA entry price of $7.49 vs. today's $10.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.45 | $1,115.34 | +11.5% |
| 1 month ago | $4.99 | $2,112.22 | +111.2% |
| 3 months ago | $5.26 | $2,003.8 | +100.4% |
| 6 months ago | $15.1 | $698.01 | -30.2% |
| 1 year ago | $7.49 | $1,407.21 | +40.7% |
| All time (5.0y) ago | $349.25 | $30.18 | -97.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ATRA forecast.
Our base-case forecast reaches $21.00 around 2030.
Implied market cap at $21.00: $189.21M
Looking further out, the multi-year forecast shows substantial upside beyond 2026. The 2030 average price is $26.19 with a max of $45.65 and a min of $16.10, delivering an ROI of 148.4% and a bullish sentiment.
The next milestone years show continued upside, with 2040 averaging $73.73 and a max of $162.18 (ROI 599.5%) and 2050 averaging $159.00 with a max of $365.71 (ROI 1408.6%), both rated BULLISH. The forecast also traces year-by-year momentum from 2027 onward as bullish, set against an annualized volatility of 100% that highlights substantial risk alongside the potential rewards.
Overall, the outlook points to meaningful long-term appreciation in later years, tempered by substantial uncertainty and the possibility of wide price swings in the near term.
Tap a question to reveal the answer.
Avg $26.19; min $16.10; max $45.65; ROI 148.4%; sentiment BULLISH.
Forecasts show rising averages in later years with bullish sentiment from 2028 onward; 2028 avg $13.30, 2029 avg $17.77, 2030 avg $26.19 and ROI rising to 148.4% by 2030, but these are estimates and not guarantees.
Yes, the forecast max is $45.65 in 2030 and $53.15 in 2031, indicating a path to or beyond $50 by 2031.
$7.08 to $15.68.
Current price $10.54; Market cap $94.97M.
Atara Biotherapeutics, Inc. Community Discussion
0Share your Atara Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.